Non Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis Drug Development Pipeline Review, 2018; New Report Launched

Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018 report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players active in this space, and also features data for dormant and discontinued projects.

NAFLD and NASH represent considerable burdens for healthcare systems, particularly in developed countries where NAFLD is the most common liver disorder.

NAFLD is strongly related to insulin resistance and is therefore often treated by therapeutics originally intended for use in diabetes mellitus. Up to 80% of obese people have NAFLD, which is usually asymptomatic or mildly symptomatic.

NASH is a severe form of NAFLD. It presents as a swelled or inflamed liver and may result in cirrhosis and consequent liver failure. As populations age the incidence of NASH is likely to rise and become a major healthcare concern for western systems.

Scope

• Which companies are the most active within the pipeline for NAFLD and NASH therapeutics?
• Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Spanning over 159 pages “Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018” report covers Introduction, Therapeutics Development, Therapeutics Assessment, Companies Involved in Therapeutics Development, Dormant Projects, Discontinued Products, Product Development Milestones, Appendix. This report Covered Companies few are - Assembly Biosciences Inc, AstraZeneca Plc, BASF SE, Betagenon AB, Bird Rock Bio Inc, BLR Bio LLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Cadila Healthcare Ltd, Can-Fite BioPharma Ltd, Cardax Inc, Carmot Therapeutics Inc, Catabasis Pharmaceuticals Inc, Cerenis Therapeutics Holding SA.

Please visit this link for more details: http://mrr.cm/U7S

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare